Autosomal Dominant Polycystic Kidney Disease Pipeline Drugs Report 2025: Innovative Treatments, Drug Candidates, Clinical Trials and Market Trends

DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Pipeline Insight 2025" report provides comprehensive insights about 13+ companies and 14+ pipeline drugs in the Autosomal Dominant Polycystic Kidney Disease pipeline landscape. It covers the Autosomal Dominant Polycystic Kidney Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Autosomal Dominant Polycystic Kidney Disease Pipeline? Click here to explore the therapies and trials making headlines @ Autosomal Dominant Polycystic Kidney Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Autosomal Dominant Polycystic Kidney Disease Pipeline Report

* On 30 September 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
* On 29 September 2025, AbbVie conducted a study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed in 1 of 4 groups, called treatment arms.
* DelveInsight's Autosomal Dominant Polycystic Kidney Disease Pipeline report depicts a robust space with 13+ active players working to develop 14+ pipeline therapies for Autosomal Dominant Polycystic Kidney Disease treatment.
* The leading Autosomal Dominant Polycystic Kidney Disease Companies such as Poxel, Regulus Therapeutics, AceLink Therapeutics, DiNAQOR AG, Shanghai Alebund Pharmaceuticals, Rege Nephro and others.
* Promising Autosomal Dominant Polycystic Kidney Disease Therapies such as Empagliflozin 10 MG, Bosutinib, ABBV-CLS-628, Tolvaptan, Tesevatinib, Lixivaptan, Everolimus, OPC-41061, VX-407 and others.

Want to know which companies are leading innovation in Autosomal Dominant Polycystic Kidney Disease? Dive into the full pipeline insights @ Autosomal Dominant Polycystic Kidney Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Autosomal Dominant Polycystic Kidney Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Autosomal Dominant Polycystic Kidney Disease Pipeline Report also highlights the unmet needs with respect to the Autosomal Dominant Polycystic Kidney Disease.

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal Dominant Polycystic Kidney Disease, an inherited kidney disease, is characterized by the relentless development and growth of cysts, causing progressive kidney enlargement associated with hypertension, abdominal fullness and pain, episodes of cyst hemorrhage, gross hematuria, nephrolithiasis, cyst infections, and reduced quality of life (QOL). Despite continuous destruction of renal parenchyma, compensatory hyperfiltration in surviving glomeruli maintains renal function within the normal range for decades.

Autosomal Dominant Polycystic Kidney Disease Emerging Drugs

* RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease.

* AL1311: AceLink Therapeutics

AL1311 is a highly potent NRF2 activator that is being developed for Autosomal Dominant Polycystic Kidney disease (ADPKD). AL1311 is different from other electrophilic and reactive NRF2 activators because it works by disrupting the protein-protein interaction between NRF2 and its regulatory protein Keap1. Non-reactive NRF2 activators have the potential to have better specificity for NRF2 activation and therefore a better safety profile. The drug is in the preclinical phase for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease.

If you're tracking ongoing Autosomal Dominant Polycystic Kidney Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Autosomal Dominant Polycystic Kidney Disease Treatment Drugs [https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Autosomal Dominant Polycystic Kidney Disease Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Autosomal Dominant Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Autosomal Dominant Polycystic Kidney Disease Treatment.
* Autosomal Dominant Polycystic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Autosomal Dominant Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Autosomal Dominant Polycystic Kidney Disease market.

Autosomal Dominant Polycystic Kidney Disease Companies

Poxel, Regulus Therapeutics, AceLink Therapeutics, DiNAQOR AG, Shanghai Alebund Pharmaceuticals, Rege Nephro and others.

Autosomal Dominant Polycystic Kidney Disease Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Autosomal Dominant Polycystic Kidney Disease Products have been categorized under various Molecule types such as,

* Monoclonal antibody
* Small molecule
* Peptide

From emerging drug candidates to competitive intelligence, the Autosomal Dominant Polycystic Kidney Disease Pipeline Report covers it all - check it out now @ Autosomal Dominant Polycystic Kidney Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Autosomal Dominant Polycystic Kidney Disease Pipeline Report

* Coverage- Global
* Autosomal Dominant Polycystic Kidney Disease Companies- Poxel, Regulus Therapeutics, AceLink Therapeutics, DiNAQOR AG, Shanghai Alebund Pharmaceuticals, Rege Nephro, and others.
* Promising Autosomal Dominant Polycystic Kidney Disease Therapies- Empagliflozin 10 MG, Bosutinib, ABBV-CLS-628, Tolvaptan, Tesevatinib, Lixivaptan, Everolimus, OPC-41061, VX-40,7 and others.
* Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Autosomal Dominant Polycystic Kidney Disease Treatment landscape in this detailed analysis @ Autosomal Dominant Polycystic Kidney Disease Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Autosomal dominant polycystic kidney disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Autosomal dominant polycystic kidney disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RGLS8429: Regulus Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AL1311: AceLink Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Autosomal dominant polycystic kidney disease Key Companies
* Autosomal dominant polycystic kidney disease Key Products
* Autosomal dominant polycystic kidney disease- Unmet Needs
* Autosomal dominant polycystic kidney disease- Market Drivers and Barriers
* Autosomal dominant polycystic kidney disease- Future Perspectives and Conclusion
* Autosomal dominant polycystic kidney disease Analyst Views
* Autosomal dominant polycystic kidney disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=autosomal-dominant-polycystic-kidney-disease-pipeline-drugs-report-2025-innovative-treatments-drug-candidates-clinical-trials-and-market-trends]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.